Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.

Trial Details

NCT ID
NCT05098132
Phase
PHASE1 / PHASE2
Sponsor
Synthekine
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • STK-012
  • pembrolizumab
  • pemetrexed
  • carboplatin
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Fullerton, California, United States|33.87029,-117.92534
  • La Jolla, California, United States|32.84727,-117.2742
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • Phase 1: Selected advanced solid tumors
  • Diagnosis of non-small cell lung cancer (NSCLC).
  • Stage IV or Stage IIIB/IIIC and not a candidate for definitive treatment.
  • Non-squamous (NSQ) cell histology.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →